Inactive Instrument

BioDelivery Sciences International, Inc. Stock price

Equities

BDSI

US09060J1060

Pharmaceuticals

Dynamic Chart
Tranche Update on BioDelivery Sciences International, Inc.'s Equity Buyback Plan announced on November 4, 2020. CI
Collegium Pharmaceutical Completes Acquisition of BioDelivery Sciences MT
BioDelivery Sciences International, Inc.(NasdaqGS:BDSI) dropped from NASDAQ Composite Index CI
BioDelivery Sciences International, Inc.(NasdaqGS:BDSI) dropped from S&P Global BMI Index CI
BioDelivery Sciences International, Inc.(NasdaqGS:BDSI) dropped from S&P TMI Index CI
Collegium Pharmaceutical, Inc. completed the acquisition of BioDelivery Sciences International, Inc. for approximately $670 million. CI
BioDelivery Sciences International, Inc.(NasdaqGS:BDSI) dropped from NASDAQ Biotechnology Index CI
Tranche Update on BioDelivery Sciences International, Inc.'s Equity Buyback Plan announced on November 4, 2020. CI
BioDelivery Sciences International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Truist Securities Downgrades BioDelivery Sciences International to Hold From Buy, Adjusts Price Target to $5.60 From $7 MT
BioDelivery Sciences International Launches Oral Solution for Acute Treatment of Migraine in US MT
Biodelivery Sciences International Announces ELYXYB Is Now Available in the U.S. for the Acute Treatment of Migraine CI
Northland Downgrades BioDelivery Sciences International to Market Perform From Outperform, Lowers Price Target to $5.60 From $7 MT
Piper Sandler Downgrades BioDelivery Sciences International to Neutral From Overweight, Lifts Price Target to $5.60 From $5 MT
Collegium Pharmaceutical to Acquire BioDelivery Sciences in All-Cash Deal; Shares Jump MT
More news
Managers TitleAgeSince
Chief Executive Officer 53 22-03-21
Director of Finance/CFO 48 22-03-21
General Counsel 40 -
More insiders
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Company builts a portfolio of products that includes utilizing its BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's product candidates include BELBUCA (buprenorphine buccal film), CIII, for chronic pain; Symproic (naldemedine), for opioid induced constipation; ELYXYB (celecoxib oral solution) for acute treatment of migraine, and ONSOLIS (fentanyl buccal soluble film) for breakthrough cancer pain.
More about the company
  1. Stock
  2. Equities
  3. Stock BioDelivery Sciences International, Inc. - Nasdaq